Maxwell Skor
Stock Analyst at Morgan Stanley
(2.54)
# 2,212
Out of 5,162 analysts
7
Total ratings
50%
Success rate
22.79%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Maxwell Skor
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MNPR Monopar Therapeutics | Initiates: Overweight | $115 | $57.60 | +99.65% | 1 | Jan 9, 2026 | |
| INSM Insmed | Maintains: Equal-Weight | $126 → $144 | $139.52 | +3.21% | 1 | Aug 21, 2025 | |
| ASND Ascendis Pharma | Assumes: Overweight | $250 | $229.01 | +9.17% | 1 | Jul 3, 2025 | |
| SANA Sana Biotechnology | Assumes: Overweight | $12 | $3.09 | +288.35% | 1 | Jul 3, 2025 | |
| TCRX TScan Therapeutics | Assumes: Overweight | $10 | $1.13 | +784.96% | 1 | Mar 14, 2025 | |
| IVVD Invivyd | Maintains: Overweight | $9.5 → $3.55 | $1.80 | +97.22% | 2 | Nov 20, 2024 |
Monopar Therapeutics
Jan 9, 2026
Initiates: Overweight
Price Target: $115
Current: $57.60
Upside: +99.65%
Insmed
Aug 21, 2025
Maintains: Equal-Weight
Price Target: $126 → $144
Current: $139.52
Upside: +3.21%
Ascendis Pharma
Jul 3, 2025
Assumes: Overweight
Price Target: $250
Current: $229.01
Upside: +9.17%
Sana Biotechnology
Jul 3, 2025
Assumes: Overweight
Price Target: $12
Current: $3.09
Upside: +288.35%
TScan Therapeutics
Mar 14, 2025
Assumes: Overweight
Price Target: $10
Current: $1.13
Upside: +784.96%
Invivyd
Nov 20, 2024
Maintains: Overweight
Price Target: $9.5 → $3.55
Current: $1.80
Upside: +97.22%